Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from tr...
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic options are absent. We report the safety of a fully human polyclo...
Alternative Titles
Full title
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5871563
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5871563
Other Identifiers
ISSN
1473-3099,1474-4457
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(18)30002-1
